BIOMARKERS OF ATHEROSCLEROSIS IN SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)

这个子项目是许多研究子项目中利用 资源由NIH/NCRR资助的中心拨款提供。子项目和 调查员(PI)可能从NIH的另一个来源获得了主要资金， 并因此可以在其他清晰的条目中表示。列出的机构是 该中心不一定是调查人员的机构。 心血管疾病(CVD)是一种缓慢发展的动脉硬化，导致中风、心脏病发作和四肢血流丧失。导致心绞痛(胸痛)、腿部抽筋或心脏病发作的心血管疾病只是心血管疾病的最后阶段。疾病的早期阶段早在生命的前十年就开始了。因此，为了减少中风和心脏病发作的患者数量，应确定处于心血管疾病早期阶段的患者进行治疗。目前的心血管疾病风险标记物只确定了60%-70%的后来会发生心脏病的人。心血管疾病在狼疮(SLE)等疾病中更为常见。事实上，SLE患者患心血管疾病的风险是普通人群的十倍。然而，在普通人群中识别早期心血管疾病的标志物在SLE患者中并不起作用。系统性红斑狼疮患者需要心血管疾病的早期标志物(生物标志物)，以便那些有心血管疾病风险的人可以接受治疗，以预防心脏病发作和中风。这项研究是为了确定系统性红斑狼疮早期心血管疾病的标志物。这项研究是由美国狼疮基金会赞助的。本研究的目的是确定系统性红斑狼疮患者心血管疾病的标志物。受试者被要求参与这项研究，因为他们的年龄在18岁到80岁之间，并且被诊断出患有狼疮(SLE)。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Cardiovascular disease (CVD) is a slowly advancing "hardening" of the arteries that leads to strokes, heart attacks, and loss of blood flow to limbs. CVD that leads to angina (chest pain), cramping of the legs, or heart attacks is only the last phase of CVD. The early phases of disease begin as early as the first ten years of life. Therefore, to reduce the number of patients who suffer from strokes and heart attacks, people who are in the early phases of CVD should be identified for treatment. Current markers of risk for CVD identify only 60-70% of those who will later have heart attacks. CVD is much more common in patients with diseases such as lupus (SLE). In fact, the risk for CVD among patients with SLE is up to ten times that of the general population. However, markers that identify early CVD in the general population do not work as well in SLE patients. Early markers (biomarkers) of CVD are needed for SLE patients so that those at risk for CVD can have treatment to prevent heart attacks and strokes. This study is being undertaken to identify such markers of early CVD in SLE. This research is sponsored by the Lupus Foundation of America. The purpose of this study is to identify markers of CVD in patients with SLE. Subjects are being asked to participate in this study because they are between the ages of 18 and 80 and have been diagnosed with lupus (SLE).